Evidence map›Paper›PMID 42064073›Full record

ReviewFrontiers in immunology2026

Immune cells in liver injury: from pathogenic mechanisms to immunotherapy.

Hao Liao, Jie Zhang, JiHao Zhang, Yajin Chen, Xiong Chen, Yuan Meng, Jie Chen

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hao Liao *Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Jie Zhang *Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
JiHao ZhangDepartment of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Yajin ChenDepartment of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Xiong ChenHepatobiliary and Pancreatic Medical Treatment Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Yuan MengHepatobiliary and Pancreatic Medical Treatment Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Jie ChenDepartment of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune regulation is an essential process via which the immune system detects initial damage signals and initiates a response to preserve microenvironmental balance. In chronic liver illnesses (such as NAFLD, NASH, or viral hepatitis), a disruption in homeostasis results in sustained inflammation and the progression of liver fibrosis, a critical factor influencing long-term morbidity and death in patients. Liver inflammation is a multifaceted physiological reaction triggered by the combined influence of several signals from both internal and external sources. Recent advancements in single-cell and spatial transcriptomics have elucidated the mechanisms that regulate the heterogeneity, spatial distribution, and autophagic characteristics of diverse intrahepatic immune cell populations, such as macrophages, neutrophils, T cells, and non-classical lymphocytes. The immune responses meticulously govern the activation of hepatic stellate cells (HSCs), their subpopulation dynamics, and their transdifferentiation into myofibroblasts via a network of chemokines and cytokines. Due to the considerable unmet clinical requirements in NAFLD/NASH, thorough investigation of the mechanisms underlying liver inflammation and fibrosis has resulted in the identification of numerous promising treatment targets. This review intends to systematically elucidate the interactions between inflammatory mediators and immune cells, alongside the fibrotic signaling pathways and their regulation mechanisms in sick livers. It emphasizes recent clinical advancements in cell therapy for liver injury treatment, aiming to establish a theoretical basis for precise therapies in liver fibrosis.

Indexed as

ImmunotherapyLiverLiver CirrhosisLiver DiseasesAnimalsHepatic Stellate CellsHumansMacrophagesSignal TransductionHSCimmune cellsimmunotherapyliver fibrosisliver injury

Identifiers

PMID42064073
PMCPMC13124578

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.